Webinar: Generation and discovery of high affinity antibodies
Our webinar “Generation and discovery of high affinity antibodies” was live on April 27, 2022 at 1PM EDT.
In this webinar, we will
- Introduce Biocytogen’s Antibody Discovery Service capabilities, which includes multiple screening technologies and accommodates antibody discovery needs for multiple species, including human, mouse, and rat.
- Provide proof-of-concept data supporting the robust capabilities of the platform to identify high-quality antibodies with therapeutic potential.
About the Speaker & Panelists
Speaker:
Li Hui, MD, Ph.D. Director, Antibody Discovery & RenMice Licensing, Biocytogen Boston
Dr. Li Hui is the Director of Antibody discovery and RenMice platforms, and is supporting the global antibody licensing effort at Biocytogen. She has broad antibody discovery experience spanning more than a decade. Before joining Biocytogen, Dr. Hui worked as Team leader, Senior Principal Scientist, custom monoclonal antibody discovery at ABclonal Technology. Prior to ABclonal Technology, Dr.Hui was a senior development scientist and project manager of monoclonal antibody discovery at Cell Signaling Technology. Dr. Hui completed her medical training in China and earned her PhD in Molecular Cell Biology at City University of New York. Her postdoctoral training at Novartis Institutes for Biomedical Research focused on target identification and drug discovery.
Moderator:
Jenna Frame, Ph.D. Manager, Scientific Communications & Marketing, Biocytogen Boston
Dr. Jenna Frame has worked with mouse and zebrafish models in the hematology field for over 15 years at the University of Rochester and Harvard Medical School. At Biocytogen, Jenna helps provide researchers with the information they need to select quality animal models and other preclinical services to advance their research pipeline.
Panelist:
Qingcong Lin, Ph.D. Senior Vice President and CEO of Biocytogen Boston
Dr. Lin has extensive research expertise in the field of molecular genetics. He has held leadership positions at Wyeth and Pfizer, and has served as the Director of the Laboratory for Genetic Engineering at the Center for Genetics and Genomics Research at Harvard Medical School. In 2018, Dr. Lin joined Biocytogen as the Senior Vice President and President of Biocytogen Boston. He is fully responsible for the company’s US and EU business development, including licensing the use of RenMab mice, the external authorization and cooperative development of therapeutic antibody candidates, including pharmacology and efficacy studies, and development of gene targeting business.
Panelist:
Clarke Gasper, Ph.D. Senior Business Development Manager, Biocytogen Boston
Dr. Clarke Gasper’s research experience ranges from protein biochemistry and structural biology to antibody production and small molecule drug development. He began his research at San Diego State University working on the myosin chaperone protein UNC-45. He then went on to Caltech, where he was part of the NIH ENCODE research consortium managing their transcription factor antibody production pipeline and developed a fully automated chromatin immunoprecipitation assay for identifying transcription factor binding sites in the human genome. He went on to receive his Ph.D. in biochemistry from Boston University where he helped identify several small-molecules, lead candidates for treating diabetes and obesity. After 13 years in scientific research, he has joined Biocytogen, where he is currently a senior business development manager.
